The goal of the study was to investigate if quantitative ADC can be used as an early imaging biomarker for predicting the treatment response to chemoradiation in esophageal cancer. Using pathological findings as the gold standard, our study demonstrated that the change in quantitative ADC from baseline (before treatment) to interim (two weeks after the initiation of treatment) was highly predictive of whether patients had residual tumors at the end of their treatment.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords